The Federal Competition Commission (CFC) has announced that it is barring Nestle SA from buying Pfizer Inc’d infant formula arm in Mexico, citing competition concerns. The deal would have been made for $11.85 billion, as Nestle outbid Groupe Danone SA last April to buy the infant formula business. The CFC determined that the eventual 71 percent stake in the sector for stage one and two formula, and an 88 percent stake for stage three formula, would be too much of a dominant position for Nestle. The CFC used quantitative techniques to come to its conclusion.
Featured News
Fifth Circuit Upholds Dismissal of Antitrust Suit Against NAR
Sep 10, 2026 by
CPI
Saudi Wealth Fund Weighs Merger of EA and Savvy Games
Sep 10, 2026 by
CPI
South Korea Antitrust Regulator Pushes Back on Korean Air Bid to Ease Merger Curbs
Sep 10, 2026 by
CPI
China’s Top Court Steps Up Antitrust Enforcement Push
Sep 10, 2026 by
CPI
US Justice Department Examines Nvidia’s $17 Billion Groq Deal
Sep 10, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 27, 2026 by
CPI
CPI Talks… with Jonathan Skrmetti, Attorney General of Tennessee
Aug 27, 2026 by
Jonathan Skrmetti
What the Live Nation Jury Instructions Tell Us About California’s Unfair Competition Law
Aug 27, 2026 by
Henry Hauser, Brent Nakamura, Ashley Kaplan, Brian Wang & Cari Jeffries
From Backroom Deals to Public Scrutiny: The Tunney Act’s Past, Present, and Future
Aug 27, 2026 by
Christina M. Black & Ashley A. Locke
Understanding the Fragility of Economic Concentration Through the Principles of Ecology
Aug 27, 2026 by
Alexandra Spring